🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Idiopathic Pulmonary Fibrosis
Clinical trial register · United States · industry-sponsored

Idiopathic Pulmonary Fibrosis Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
Florida 10 California 9 Alabama 7 Colorado 6 Kansas 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Boehringer Ingelheim2 Daewoong Pharmaceutical Co. LTD.1 PureTech1 AbbVie1 Bristol-Myers Squibb1
State
Florida10 California9 Alabama7 Colorado6 Kansas6
All 27 states
Target enrolment
to
12 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
NCT07516951Idiopathic Pulmonary Fibrosis
Chiesi Farmaceutici S.p.A.
Phase 2
240
Texas
2026-07-08
Recruiting
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
NCT07671911Idiopathic Pulmonary Fibrosis
Trevi Therapeutics
Phase 3
306
California, Colorado, Florida, Louisiana, Missouri, North Carolina, Pennsylvania, South Carolina
2026-06-29
Recruiting
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
NCT07230288Idiopathic Pulmonary Fibrosis
AbbVie
Phase 2
165
Alabama, Florida, Illinois, Michigan, Missouri, Pennsylvania, Virginia
2026-01-23
Recruiting
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
NCT07036523Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim
Phase 2
71
Alabama, Florida, Iowa, Kansas, Minnesota, Missouri, New York, North Carolina
2025-11-13
Active, closed
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
NCT06736990Idiopathic Pulmonary Fibrosis
Calluna Pharma AS
Phase 2
150
California, Colorado, Florida, Kansas, North Carolina, Ohio, Pennsylvania, Utah
2025-06-20
Recruiting
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06967805Idiopathic Pulmonary Fibrosis
Mediar Therapeutics
Phase 2
164
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-05-05
Recruiting
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Boehringer Ingelheim
Phase 3
1,700
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2024-05-06
Recruiting
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05571059Idiopathic Pulmonary Fibrosis
Cumberland Pharmaceuticals
Phase 2
128
California, Connecticut, Florida, Illinois, Indiana, Kansas, Kentucky, Michigan
2024-01-31
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426Idiopathic Pulmonary Fibrosis
Bristol-Myers Squibb
Phase 3
1,255
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2023-09-14
By invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
United Therapeutics
Phase 3
1,850
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2022-09-06
Active, closed
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
NCT05389215Idiopathic Pulmonary Fibrosis
Daewoong Pharmaceutical Co. LTD.
Phase 2
102
Arizona, California, Illinois, Kansas, Massachusetts, Michigan, Missouri, North Carolina
2022-07-29
Active, closed
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05321420Idiopathic Pulmonary Fibrosis
PureTech
Phase 2
240
Alabama, California, Connecticut, Florida, Georgia, Indiana, Kansas, North Carolina
2022-07-22
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/idiopathic-pulmonary-fibrosis

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.